FDAnews Drug Daily Bulletin
Pharmaceuticals / Commercial Operations

Kaléo Promises Generic Naloxone Injector After Blistering Senate Pricing Report

Jan. 7, 2019
A A

A month after a scathing congressional report hit Kaléo for hiking prices for its opioid antidote by 600 percent, the company announced it will release a lower-cost generic version of its auto-injector in 2019.

Kaléo also announced that, effective immediately, it will make its branded naloxone auto-injector Evzio available at $178 per carton to government agencies, first responders and health departments that purchase directly from the company or its authorized distributors.

Last month, the Senate Homeland Security and Governmental Affairs Committee’s investigations subcommittee issued a report that found Kaléo artificially inflated price hikes for Evzio over the past four years. The company ignored industry experts’ recommendations to set prices for the injector between $250 to $300 per unit, according to the report, instead charging $575 per unit and eventually increasing the price to $4,100.

View today's stories